Technology evaluation: colostrinin, ReGen.
ReGen Therapeutics is developing Colostrinin, a polypeptide complex derived from ovine colostrums, for the potential treatment of Alzheimer's disease. The compound is currently undergoing phase II clinical trials.
Rattray
Marcus
M
King's College London, The Wolfson Centre for Age-Related Diseases, London, UK. marcus.rattray@kcl.ac.uk
D000544:Alzheimer Disease / Q000188:drug therapy*; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003126:Colostrum / Q000737:chemistry*; D005260:Female; D006801:Humans; D016716:PC12 Cells; D010455:Peptides / Q000737:chemistry* / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011247:Pregnancy; D051381:Rats
D010455:Peptides